3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow cagrilintide: new trials by email Literature Review of cagrilintide trials Research Report on cagrilintide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease NNC0194-0499, Semaglutide, NNC0194-0499 placebo - Alcohol-related Liver Disease | Phase 2 | Completed | Novo Nordisk A/S | 270 | 2024-05-20 | 2026-03-12 |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo Cagrilintide, Semaglutide, Placebo - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Completed | Novo Nordisk A/S | 626 | 2024-04-01 | 2026-09-24 |
| Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes Semaglutide 2.4 mg, Cagrilintide 2.4 mg, Placebo (semaglutide) - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Novo Nordisk A/S | 92 | 2021-08-02 | 2025-12-23 |
Diabetes Mellitus, Type 2 (2) · Obesity (1) · Renal Insufficiency, Chronic (1)
Novo Nordisk A/S (3)
United States (3) · Canada (2) · France (2) · Greece (2) · Japan (2) · Poland (2) · Spain (2) · Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1)
2023 (2)